Upadacitinib

Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, AbbVie announced in a press release.

Patients with moderate to severe ulcerative colitis achieved critical clinical, endoscopic and histological outcomes on maintenance doses of upadacitinib compared with placebo, with no new safety risks reported, according to study results.

Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.

Researchers have dosed the first patient in Step-Up HS, a phase 3 study evaluating Rinvoq for moderate to severe hidradenitis suppurativa in adults and adolescents, AbbVie announced in a press release.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Patients with psoriatic arthritis and axial involvement experienced greater improvement when treated with upadacitinib 15 mg compared with placebo and adalimumab, according to data published in Arthritis Research & Therapy.

Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment, according to a study.

The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.

Compared with adults, upadacitinib exhibited similar efficacy and safety results in adolescents aged 12 to 17 years in the treatment of moderate to severe atopic dermatitis, according to a study.